Mark studied Chemistry at the University of East Anglia and Imperial College London and worked for eleven years in the pharmaceutical industry before retraining as a health economist. He joined King’s Health Economics as a senior lecturer in 2015. Mark’s interests include the extrapolation of event data in decision analytic models, the valuation of health benefits using willingness-to-pay methods, and the application of economic evaluation in dentistry. He has undertaken extensive work applying cost-effectiveness analysis in total joint arthroplasty, which utilised innovative methods to analyse large observational datasets. He has published analysis from the largest ever survey of the monetary valuation of health benefits (EuroVaQ) which indicated that the general public places higher monetary values on health gains which extend life compared to those which improve quality of life. He has also published methodological work on the appropriate statistical analysis of non-response in contingent valuation surveys.
Mark leads the team which provides economic analysis for King’s Technology Evaluation Centre (KiTEC). KiTEC is one of three external assessment centres which undertake technology assessments for the National Institute of Health & Care Excellence (NICE). As part of that role he is leading the economic analysis of three NHS England Commissioning through Evaluation projects which will evaluate: radiotherapy targeting technology in cancer; surgery to enhance mobility and reduce pain for children with cerebral palsy; and monoclonal antibody therapy for kidney disease. He is currently leading the economic evaluation of a trial investigating 3-dimensional scanning technology for breast screening which will follow 100,000 women over seven years. He is also the primary supervisor for a PhD student investigating the cost-effectiveness and acceptability of screening for BRCA1/2 gene mutation in Kazakhstan, and the second supervisor for a PhD student investigating the economics of caries prevention.
Further information available.